INNOVIVA, INC. Payments for (Proceeds from) Other Investing Activities
INNOVIVA, INC. (INVA) reported Payments for (Proceeds from) Other Investing Activities of $92.95 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2022-11-09
- INNOVIVA, INC. payments for (proceeds from) other investing activities for the quarter ending 2022-09-30 was $54.92M, a 53.38% increase year-over-year.
- INNOVIVA, INC. payments for (proceeds from) other investing activities for the quarter ending 2022-06-30 was $36.01M, a 19.84% increase year-over-year.
- INNOVIVA, INC. payments for (proceeds from) other investing activities for the quarter ending 2022-03-31 was $2.02M, a 98.21% decline year-over-year.
- INNOVIVA, INC. payments for (proceeds from) other investing activities for the quarter ending 2021-12-31 was -$369.42M.
- INNOVIVA, INC. payments for (proceeds from) other investing activities for fiscal 2021 was -$190.97M.
- INNOVIVA, INC. payments for (proceeds from) other investing activities for fiscal 2020 was -$14.88M.
- INNOVIVA, INC. payments for (proceeds from) other investing activities for fiscal 2019 was $0.00.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|
| 2022-09-30 | $54.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $90.94M derived: sum of 2 quarters · filed 2022-11-09 | $92.95M 10-Q · filed 2022-11-09 | -$276.46M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $36.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $38.03M 10-Q · filed 2022-07-27 | -$331.39M derived: sum of 3 quarters · filed 2022-07-27 | -$295.58M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $2.02M 10-Q · filed 2022-05-05 | -$367.40M derived: sum of 2 quarters · filed 2022-05-05 | -$331.59M derived: sum of 3 quarters · filed 2022-11-09 | -$301.54M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | -$369.42M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | -$333.61M derived: sum of 2 quarters · filed 2022-11-09 | -$303.56M derived: sum of 3 quarters · filed 2022-11-09 | -$190.97M 10-K/A · filed 2022-03-17 |
| 2021-09-30 | $35.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $65.86M derived: sum of 2 quarters · filed 2022-11-09 | $178.44M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $30.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $142.64M 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $112.59M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$14.88M 10-K/A · filed 2022-03-17 | |||
| 2019-12-31 | $0.00 10-K/A · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |